In 2003, Scott M. Rocklage, PhD, became a venture partner of 5AM Ventures, and in 2004 he became one of its managing partners. Rocklage has managed healthcare for over thirty years. His management career has included strategic leadership responsibilities, and his performance in these roles eventually led to the FDA approval of three US drug applications for Cubicin, Teslascan, and Omniscan.
His actions included entering several drug candidates into clinical trials. He held positions in senior management of Cubist Pharmaceuticals and Nycomed Salutar. He was committed to and advanced both the research and development at the Catalytica and Salutar corporations. Scott Rocklage has been a member of various corporate boards, including that of Novira and Relypsa. Novira was later taken over by Johnson & Johnson. At present, Dr. Rocklage demonstrates an extraordinary amount of energy and passion, in serving on multiple boards of companies. He chairs the Board of Rennovia, Kenestral, and Cidara corporations. He also continues to serve on the Board at both the Epirus and Pulmatrix companies.
He served in the past as Executive Chairman of Miikana; later on, EntreMed acquired this corporation. Included on his list of executive and leadership roles also was the Executive Chair at Ilypsa ; Amgen acquired this business later on. He continues to chair Semprus, which was acquired later by Teleflex. His highest academic degree is a PhD in Chemistry from the Massachusetts Institute of Technology (MIT). At MIT, his noted research was conducted in a laboratory of the 2005 Chemistry Nobel Prize Winner, Richard R. Schrock. Scott has both invented and co-invented over 30 U.S. patents, and written over 100 publications. All of these publications were peer reviewed. Dr. Rocklage works out of his Boston, MA office.
His work involves studying new topics in life science, working with the management team to make investment decisions for the company portfolio, and conducting board meetings for the corporation. He works with entrepreneurs such as physicians, scientists, and business-executives, for the purpose of assisting them in developing ideas for formulating medicines. These new medicines are used in the treatment of diseases, where scientists are in an intensive search for a cure.
He shows particular interest in the increasing ability to target genotypes or specific mutation. These are useful for treating cancer in effective and innovative ways. He believes that these developments have already saved and extended lives. Scott embraces the entrepreneurial quality of taking calculated risks. He feels the best direction for individuals is to always embrace the entrepreneurial spirit, rather than to work for reputable, established Fortune 500 companies.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.